Structural and functional basis of cyclooxygenase inhibition

Journal of Medicinal Chemistry

Volumn 50, Issue 7, 2007, Pages 1425-1441

  Blobaum, Anna L ^a   Marnett, Lawrence J ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2 METHYL 4 PHENYLOXAZOL 5 YL)BENZENESULFONAMIDE; 4 [5 (4 BROMOPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; 5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; ACETYLSALICYLIC ACID; ALCLOFENAC; BENZENESULFONAMIDE DERIVATIVE; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; ETORICOXIB; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; LUMIRACOXIB; MEFENAMIC ACID; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PLACEBO; PROSTAGLANDIN D2; PROSTAGLANDIN G2; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; SC 299; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALDECOXIB;

AMINO ACID SEQUENCE; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR DISEASE; CATALYSIS; CATALYST; CLINICAL TRIAL; COLON POLYP; CRYSTAL STRUCTURE; DRUG EFFECT; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME INHIBITOR COMPLEX; FEVER; HEART INFARCTION; HISTORY OF MEDICINE; HUMAN; HYDROPHOBICITY; LOW DRUG DOSE; PAIN; PROTEIN EXPRESSION; REACTION ANALYSIS; RECTUM POLYP; REVIEW; SEQUENCE ANALYSIS; STROKE; STRUCTURE ANALYSIS; THROMBOEMBOLISM;

ANIMALS; CARDIOVASCULAR SYSTEM; CRYSTALLOGRAPHY, X-RAY; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HISTORY, ANCIENT; HUMANS; KINETICS; MODELS, MOLECULAR; PROTEIN CONFORMATION; RISK ASSESSMENT;

EID: 34147119080     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0613166     Document Type: Review

References (117)

1. Stone, E. An account of the success of the bark of the willow in the cure of agues. Philos. Trans. R. Soc. 1763, 53, 195-200.
2. Vane, J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature (London), New Biol. 1971, 231, 232-235.
3. Ferreira, S. H.; Moncada, S.; Vane, J. R. Aspirin selectively inhibits prostaglandin production in dog spleen. Nature (London), New Biol. 1971, 231, 237-239.
4. Smith, J. B.; Willis, A. L. Aspirin selectively inhibits prostaglandin production in human platelets. Nature (London), New Biol. 1971, 231, 235-237.
5. Hamberg, M.; Samuelsson, B. Oxygenation of unsaturated fatty acids by the vesicular gland of sheep. J. Biol. Chem. 1967, 242, 5344-5354.
6. Miyamoto, T.; Ogino, N.; Yamamoto, S.; Hayaishi, O. Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J. Biol. Chem. 1976, 251, 2629-2636.
7. Xie, W. L.; Chipman, J. G.; Robertson, D. L.; Erikson, R. L.; Simmons, D. L. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 2692-2696.
8. Kujubu, D. A.; Fletcher, B. S.; Varnum, B. C.; Lim, R. W.; Herschman, H. R. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem. 1991, 266, 12866-12872.
9. Morita, I.; Schindler, M.; Regier, M. K.; Otto, J. C.; Hori, T.; DeWitt, D. L.; Smith, W. L. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J. Biol. Chem. 1995, 270, 10902-10908.
10. Smith, W. L.; DeWitt, D. L.; Garavito, R. M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 2000, 69, 145-182.
11. Marnett, L. J.; Kalgutkar, A. S. Cyclooxygenase 2 inhibitors: discovery, selectivity and the future. Trends Pharmacol. Sci. 1999, 20, 465-469.
12. Masferrer, J. L.; Zweifel, B. S.; Manning, P. T.; Hauser, S. D.; Leahy, K. M.; Smith, W. G.; Isakson, P. C.; Seibert, K. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl. Acad. Sci U.S.A. 1994, 91, 3228-3232.
13. Lefkowith, J. B.; Verburg, K. M.; Geiss, G. S. Clinical Experience with Celecoxib: A Cyclooxygenase-2 Specific Inhibitor. In Therapeutic Roles of Selective COX-2 Inhibitors; William Harvey Press: London, 2001; pp 461-481.
14. Morrison, B.; Simon, T. J.; DeTora, L.; Sperling, R. Rofecoxib: Clinical Studies. In Therapeutic Roles of Selective COX-2 Inhibitors; William Harvey Press: London, 2001; pp 541-559.
15. Arber, N.; DuBois, R. N. Nonsteroidal anti-inflammatory drugs and prevention of colorectal cancer. Curr. Gastroenterol. Rep. 1999, 1, 441-448.
16. Gupta, R. A.; Dubois, R. N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer 2001, 1, 11-21.
17. Dannenberg, A. J.; Altorki, N. K.; Boyle, J. O.; Dang, C.; Howe, L. R.; Weksler, B. B.; Subbaramaiah, K. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol. 2001, 2, 544-551.
18. Bresalier, R. S.; Sandler, R. S.; Quan, H.; Bolognese, J. A.; Oxenius, B.; Horgan, K.; Lines, C.; Riddell, R.; Morton, D.; Lanas, A.; Konstam, M. A.; Baron, J. A. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 2005, 352, 1092-1102.
19. Solomon, S. D.; McMurray, J. J.; Pfeffer, M. A.; Wittes, J.; Fowler, R.; Finn, P.; Anderson, W. F.; Zauber, A.; Hawk, E.; Bertagnolli, M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 2005, 352, 1071-1080.
20. Aldington, S.; Shirtcliffe, P.; Weatherall, M.; Beasley, R. Systematic review and meta-analysis of the risk of major cardiovascular events with etoricoxib therapy. N. Z. Med. J. 2005, 118, U1684.
21. Aldington, S.; Shirtcliffe, P.; Weatherall, M.; Beasley, R. Increased risk of cardiovascular events with parecoxib/valdecoxib: a systematic review and meta-analysis. N. Z. Med. J. 2005, 118, U1755.
22. Nussmeier, N. A.; Whelton, A. A.; Brown, M. T.; Langford, R. M.; Hoeft, A.; Parlow, J. L.; Boyce, S. W.; Verburg, K. M. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med. 2005, 352, 1081-1091.
23. Krotz, F.; Schiele, T. M.; Klauss, V.; Sohn, H. Y. Selective COX-2 inhibitors and risk of myocardial infarction. J. Vasc. Res. 2005, 42, 312-324.
24. Marnett, L. J.; Rowlinson, S. W.; Goodwin, D. C.; Kalgutkar, A. S.; Lanzo, C. A. Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. J. Biol. Chem. 1999, 274, 22903-22906.
25. Garavito, R. M.; Mulichak, A. M. The structure of mammalian cyclooxygenases. Annu. Rev. Biophys. Biomol. Struct. 2003, 32, 183-206.
26. DeWitt, D. L. Cox-2-selective inhibitors: the new super aspirins. Mol. Pharmacol. 1999, 55, 625-631.
27. Xiao, G.; Chen, W.; Kulmacz, R. J. Comparison of structural stabilities of prostaglandin H synthase-1 and -2. J. Biol. Chem. 1998, 273, 6801-6811.
28. Picot, D.; Loll, P. J.; Garavito, R. M. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 1994, 367, 243-249.
29. Yuan, C.; Rieke, C. J.; Rimon, G.; Wingerd, B. A.; Smith, W. L. Partnering between monomers of cyclooxygenase-2 homodimers. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 6142-6147.
30. Luong, C.; Miller, A.; Barnett, J.; Chow, J.; Ramesha, C.; Browner, M. F. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat. Struct. Biol. 1996, 3, 927-933.
31. Kurumbail, R. G.; Stevens, A. M.; Gierse, J. K.; McDonald, J. J.; Stegeman, R. A.; Pak, J. Y.; Gildehaus, D.; Miyashiro, J. M.; Penning, T. D.; Seibert, K.; Isakson, P. C.; Stallings, W. C. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996, 384, 644-648.
32. Malkowski, M. G.; Ginell, S. L.; Smith, W. L.; Garavito, R. M. The productive conformation of arachidonic acid bound to prostaglandin synthase. Science 2000, 289, 1933-1937.
33. Rowlinson, S. W.; Crews, B. C.; Lanzo, C. A.; Marnett, L. J. The binding of arachidonic acid in the cyclooxygenase active site of mouse prostaglandin endoperoxide synthase-2 (COX-2). A putative L-shaped binding conformation utilizing the top channel region. J. Biol. Chem. 1999, 274, 23305-23310.
34. Dietz, R.; Nastainczyk, W.; Ruf, H. H. Higher oxidation states of prostaglandin H synthase. Rapid electronic spectroscopy detected two spectral intermediates during the peroxidase reaction with prostaglandin G2. Eur. J. Biochem. 1988, 171, 321-328.
35. Smith, W. L.; Eling, T. E.; Kulmacz, R. J.; Marnett, L. J.; Tsai, A. Tyrosyl radicals and their role in hydroperoxide-dependent activation and inactivation of prostaglandin endoperoxide synthase. Biochemistry 1992, 31, 3-7.
36. Tsai, A.; Kulmacz, R. J. Tyrosyl radicals in prostaglandin H synthase-1 and -2. Prostaglandins Other Lipid Mediators 2000, 62, 231-254.
37. Kulmacz, R. J. Cellular regulation of prostaglandin H synthase catalysis. FEBS Lett. 1998, 430, 154-157.
38. Chen, W.; Pawelek, T. R.; Kulmacz, R. J. Hydroperoxide dependence and cooperative cyclooxygenase kinetics in prostaglandin H synthase-1 and -2. J. Biol. Chem. 1999, 274, 20301-20306.
39. Tsai, A.; Wu, G.; Palmer, G.; Bambai, B.; Koehn, J. A.; Marshall, P. J.; Kulmacz, R. J. Rapid kinetics of tyrosyl radical formation and heme redox state changes in prostaglandin H synthase-1 and -2. J. Biol. Chem. 1999, 274, 21695-21700.
40. Tsai, A. L.; Palmer, G.; Kulmacz, R. J. Prostaglandin H synthase. Kinetics of tyrosyl radical formation and of cyclooxygenase catalysis. J. Biol. Chem. 1992, 267, 17753-17759.
41. Kiefer, J. R.; Pawlitz, J. L.; Moreland, K. T.; Stegeman, R. A.; Hood, W. F.; Gierse, J. K.; Stevens, A. M.; Goodwin, D. C.; Rowlinson, S. W.; Marnett, L. J.; Stallings, W. C.; Kurumbail, R. G. Structural insights into the stereochemistry of the cyclooxygenase reaction. Nature 2000, 405, 97-101.
42. Thuresson, E. D.; Lakkides, K. M.; Rieke, C. J.; Sun, Y.; Wingerd, B. A.; Micielli, R.; Mulichak, A. M.; Malkowski, M. G.; Garavito, R. M.; Smith, W. L. Prostaglandin endoperoxide H synthase-1: the functions of cyclooxygenase active site residues in the binding, positioning, and oxygenation of arachidonic acid. J. Biol. Chem. 2001, 276, 10347-10357.
43. Rome, L. H.; Lands, W. E. Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs. Proc. Natl. Acad. Sci. U.S.A. 1975, 72, 4863-4865.
44. Smith, W. L.; Lands, W. E. Stimulation and blockade of prostaglandin biosynthesis. J. Biol. Chem. 1971, 246, 6700-6702.
45. Roth, G. J.; Stanford, N.; Majerus, P. W. Acetylation of prostaglandin synthase by aspirin. Proc. Natl. Acad. Sci. U.S.A. 1975, 72, 3073-3076.
46. 2-terminal serine of prostaglandin synthetase by aspirin. J. Biol. Chem. 1978, 253, 3782-3784.
47. Roth, G. J.; Siok, C. J.; Ozols, J. Structural characteristics of prostaglandin synthetase from sheep vesicular gland. J. Biol. Chem. 1980, 255, 1301-1304.
48. Van Der Ouderaa, F. J.; Buytenhek, M.; Nugteren, D. H.; Van Dorp, D. A. Acetylation of prostaglandin endoperoxide synthetase with acetylsalicylic acid. Eur. J. Biochem. 1980, 109, 1-8.
49. Roth, G. J.; Machuga, E. T.; Ozols, J. Isolation and covalent structure of the aspirin-modified, active-site region of prostaglandin synthetase. Biochemistry 1983, 22, 4672-4675.
50. DeWitt, D. L.; el-Harith, E. A.; Kraemer, S. A.; Andrews, M. J.; Yao, E. F.; Armstrong, R. L.; Smith, W. L. The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases. J. Biol. Chem. 1990, 265, 5192-5198.
51. Meade, E. A.; Smith, W. L.; DeWitt, D. L. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 1993, 268, 6610-6614.
52. Vane, J. R.; Botting, R. M. Mechanism of action of anti-inflammatory drugs. Scand. J. Rheumatol., Suppl. 1996, 102, 9-21.
53. Lecomte, M.; Laneuville, O.; Ji, C.; DeWitt, D. L.; Smith, W. L. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J. Biol. Chem. 1994, 269, 13207-13215.
54. Xiao, G.; Tsai, A. L.; Palmer, G.; Boyar, W. C.; Marshall, P. J.; Kulmacz, R. J. Analysis of hydroperoxide-induced tyrosyl radicals and lipoxygenase activity in aspirin-treated human prostaglandin H synthase-2. Biochemistry 1997, 36, 1836-1845.
55. Holtzman, M. J.; Turk, J.; Shornick, L. P. Identification of a pharmacologically distinct prostaglandin H synthase in cultured epithelial cells. J. Biol. Chem. 1992, 267, 21438-21445.
56. Rowlinson, S. W.; Crews, B. C.; Goodwin, D. C.; Schneider, C.; Gierse, J. K.; Marnett, L. J. Spatial requirements for 15-(R)-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid synthesis within the cyclooxygenase active site of murine COX-2. Why acetylated COX-1 does not synthesize 15-(R)-hete. J. Biol. Chem. 2000, 275, 6586-6591.
57. Loll, P. J.; Picot, D.; Garavito, R. M. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat. Struct. Biol. 1995, 2, 637-643.
58. Hochgesang, G. P., Jr.; Rowlinson, S. W.; Marnett, L. J. Tyrosine-385 is critical for acetylation of cyclooxygenase-2 by aspirin. J. Am. Chem. Soc. 2001, 122, 6514-6515.
59. Loll, P. J.; Sharkey, C. T.; O'Connor, S. J.; Dooley, C. M.; O'Brien, E.; Devocelle, M.; Nolan, K. B.; Selinsky, B. S.; Fitzgerald, D. J. O-Acetylsalicylhydroxamic acid, a novel acetylating inhibitor of prostaglandin H2 synthase: structural and functional characterization of enzyme-inhibitor interactions. Mol. Pharmacol. 2001, 60, 1407-1413.
60. Rowlinson, S. W.; Kiefer, J. R.; Prusakiewicz, J. J.; Pawlitz, J. L.; Kozak, K. R.; Kalgutkar, A. S.; Stallings, W. C.; Kurumbail, R. G.; Marnett, L. J. A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385. J. Biol. Chem. 2003, 278, 45763-45769.
61. Menard, R.; Storer, A. C. Oxyanion hole interactions in serine and cysteine proteases. Biol. Chem. Hoppe-Seyler 1992, 373, 393-400.
62. Chen, Y. N.; Marnett, L. J. Heme prosthetic group required for acetylation of prostaglandin H synthase by aspirin. FASEB J. 1989, 3, 2294-2297.
63. Aronoff, D. M.; Boutaud, O.; Marnett, L. J.; Oates, J. A. Inhibition of prostaglandin H2 synthases by salicylate is dependent on the oxidative state of the enzymes. J. Pharmacol. Exp. Ther. 2003, 304, 589-595.
64. Pedersen, A. K.; FitzGerald, G. A. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N. Engl. J. Med. 1984, 311, 1206-1211.
65. Rosenstock, M.; Danon, A.; Rimon, G. PGHS-2 inhibitors, NS-398 and DuP-697, attenuate the inhibition of PGHS-1 by aspirin and indomethacin without altering its activity. Biochim. Biophys. Acta. 1999, 1440, 127-137.
66. Rosenstock, M.; Danon, A.; Rubin, M.; Rimon, G. Prostaglandin H synthase-2 inhibitors interfere with prostaglandin H synthase-1 inhibition by nonsteroidal anti-inflammatory drugs. Eur. J. Pharmacol. 2001, 412, 101-108.
67. Leese, P. T.; Hubbard, R. C.; Karim, A.; Isakson, P. C.; Yu, S. S.; Geis, G. S. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J. Clin. Pharmacol. 2000, 40, 124-132.
68. Greenberg, H. E.; Gottesdiener, K.; Huntington, M.; Wong, P.; Larson, P.; Wildonger, L.; Gillen, L.; Dorval, E.; Waldman, S. A. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. J. Clin. Pharmacol. 2000, 40, 1509-1515.
69. Depre, M.; Ehrich, E.; Van Hecken, A.; De Lepeleire, I.; Dallob, A.; Wong, P.; Porras, A.; Gertz, B. J.; De Schepper, P. J. Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. Eur. J. Clin. Pharmacol. 2000, 56, 167-174.
70. Ouellet, M.; Riendeau, D.; Percival, M. D. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 14583-14588.
71. Kulmacz, R. J.; Lands, W. E. M. Stoichiometry and kinetics of the interaction of prostaglandin H synthase with anti-inflammatory agents. J. Biol. Chem. 1985, 260, 12572-12578.
72. Greig, G. M.; Francis, D. A.; Falgueyret, J. P.; Ouellet, M.; Percival, M. D.; Roy, P.; Bayly, C.; Mancini, J. A.; O'Neill, G. P. The interaction of arginine 106 of human prostaglandin G/H synthase-2 with inhibitors is not a universal component of inhibition mediated by nonsteroidal anti-inflammatory drugs. Mol. Pharmacol. 1997, 52, 829-838.
73. Kalgutkar, A. S.; Crews, B. C.; Rowlinson, S. W.; Marnett, A. B.; Kozak, K. R.; Remmel, R. P.; Marnett, L. J. Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 925-930.
74. Gierse, J. K.; Koboldt, C. M.; Walker, M. C.; Seibert, K.; Isakson, P. C. Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem. J. 1999, 339 (3), 607-614.
75. Bombardier, C.; Laine, L.; Reicin, A.; Shapiro, D.; Burgos-Vargas, R.; Davis, B.; Day, R.; Ferraz, M. B.; Hawkey, C. J.; Hochberg, M. C.; Kvien, T. K.; Schnitzer, T. J. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 2000, 343, 1520-1528.
76. Capone, M. L.; Tacconelli, S.; Sciulli, M. G.; Grana, M.; Ricciotti, E.; Minuz, P.; Di Gregorio, P.; Merciaro, G.; Patrono, C.; Patrignani, P. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 2004, 109, 1468-1471.
77. Selinsky, B. S.; Gupta, K.; Sharkey, C. T.; Loll, P. J. Structural analysis of NSAID binding by prostaglandin H2 synthase: time-dependent and time-independent inhibitors elicit identical enzyme conformations. Biochemistry 2001, 40, 5172-5180.
78. Mancini, J. A.; Riendeau, D.; Falgueyret, J. P.; Vickers, P. J.; O'Neill, G. P. Arginine 120 of prostaglandin G/H synthase-1 is required for the inhibition by nonsteroidal anti-inflammatory drugs containing a carboxylic acid moiety. J. Biol. Chem. 1995, 270, 29372-29377.
79. Prusakiewicz, J. J.; Felts, A. S.; Mackenzie, B. S.; Marnett, L. J. Molecular basis of the time-dependent inhibition of cyclooxygenases by indomethacin. Biochemistry 2004, 43, 15439-15445.
80. Mancini, J. A.; Vickers, P. J.; O'Neill, G. P.; Boily, C.; Falgueyret, J. P.; Riendeau, D. Altered sensitivity of aspirin-acetylated prostaglandin G/H synthase-2 to inhibition by nonsteroidal anti-inflammatory drugs. Mol. Pharmacol. 1997, 51, 52-60.
81. Houtzager, V.; Ouellet, M.; Falgueyret, J. P.; Passmore, L. A.; Bayly, C.; Percival, M. D. Inhibitor-induced changes in the intrinsic fluorescence of human cyclooxygenase-2. Biochemistry 1996, 35, 10974-10984.
82. Clark, K.; Kulathila, R.; Koehn, J.; Rieffel, S.; Strauss, A.; Hu, S.; Kalfoglou, M.; Szeto, D.; Lasala, D.; Sabio, M.; Wang, X.; Marshall, P. Crystal Structure of the Lumiracoxib:cyclooxygenase-2 Complex. Book of Abstracts, 228th National Meeting of the American Chemical Society, Philadelphia, PA, August 22-26, 2004; American Chemical Society: Washington, DC, 2004; pp 22-26.
83. Esser, R.; Berry, C.; Du, Z.; Dawson, J.; Fox, A.; Fujimoto, R. A.; Haston, W.; Kimble, E. F.; Koehler, J.; Peppard, J.; Quadros, E.; Quintavalla, J.; Toscano, K.; Urban, L.; van Duzer, J.; Zhang, X.; Zhou, S.; Marshall, P. J. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br. J. Pharmacol. 2005, 144, 538-550.
84. Bayly, C. I.; Black, W. C.; Leger, S.; Ouimet, N.; Ouellet, M.; Percival, M. D. Structure-based design of COX-2 selectivity into flurbiprofen. Bioorg. Med. Chem. Lett. 1999, 9, 307-312.
85. Kozak, K. R.; Prusakiewicz, J. J.; Rowlinson, S. W.; Marnett, L. J. Enantiospecific, selective cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. Lett. 2002, 12, 1315-1318.
86. Kalgutkar, A. S.; Marnett, A. B.; Crews, B. C.; Remmel, R. P.; Marnett, L. J. Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors. J. Med. Chem. 2000, 43, 2860-2870.
87. Kalgutkar, A. S.; Crews, B. C.; Saleh, S.; Prudhomme, D.; Marnett, L. J. Indolyl esters and amides related to indomethacin are selective COX-2 inhibitors. Bioorg. Med. Chem. 2005, 13, 6810-6822.
88. Moser, P.; Sallmann, A.; Wiesenberg, I. Synthesis and quantitative structure-activity relationships of diclofenac analogs. J. Med. Chem. 1990, 33, 2358-2368.
89. Brooks, C. D. W.; Craig, R. A.; Kolasa, T.; Stewart, A. O. Iminoxyderivatives of Fenamates as Inhibitors of Prostaglandin Biosynthesis. U.S. Patent 5,843,946, 1999.
90. Sorbera, L. A.; Castaner, J.; Bayes, M.; Silvestre, J. S. Lumiracoxib. Drugs Future 2002, 27, 740-747.
91. Talley, J. J. Selective inhibitors of cyclooxygenase-2 (COX-2). Prog. Med. Chem. 1999, 36, 201-234.
92. Leblanc, Y.; Gauthier, J. Y.; Ethier, D.; Guay, J.; Mancini, J. A.; Riendeau, D.; Tagari, P.; Vickers, P. J.; Wong, E.; Prasit, P. Synthesis and biological evaluation of 2,3-diarylthiophenes as selective COX-2 and COX-1 inhibitors. Bioorg. Med. Chem. Lett. 1995, 5, 2123-2128.
93. Bertenshaw, S. R.; Talley, J. J.; Rogier, D. J.; Graneto, M. J.; Rogers, R. S.; Kramer, S. W.; Penning, T. D.; Koboldt, C. M.; Veenhuizen, A. W.; Zhang, Y. 3,4-Diarylthiophenes are selective COX-2 inhibitors. Bioorg. Med. Chem. Lett. 1995, 5, 2919-2922.
94. Marnett, L. J.; Kalgutkar, A. S. Structural Diversity of Selective COX-2 Inhibitors. In COX-2 Inhibitors; Birkhauser-Verlag: Boston, MA, 2004; pp 15-40.
95. Copeland, R. A.; Williams, J. M.; Giannaras, J.; Nurnberg, S.; Covington, M.; Pinto, D.; Pick, S.; Trzaskos, J. M. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 11202-11206.
96. Guo, Q.; Wang, L. H.; Ruan, K. H.; Kulmacz, R. J. Role of Val509 in time-dependent inhibition of human prostaglandin H synthase-2 cyclooxygenase activity by isoform-selective agents. J. Biol. Chem. 1996, 271, 19134-19139.
97. Gierse, J. K.; McDonald, J. J.; Hauser, S. D.; Rangwala, S. H.; Koboldt, C. M.; Seibert, K. A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J. Biol. Chem. 1996, 271, 15810-15814.
98. Wong, E.; Bayly, C.; Waterman, H. L.; Riendeau, D.; Mancini, J. A. Conversion of prostaglandin G/H synthase-1 into an enzyme sensitive to PGHS-2-selective inhibitors by a double His513 → Arg and Ile523 → val mutation. J. Biol. Chem. 1997, 272, 9280-9286.
99. Lanzo, C. A.; Beechem, J. M.; Talley, J.; Marnett, L. J. Investigation of the binding of isoform-selective inhibitors to prostaglandin endoperoxide synthases using fluorescence spectroscopy. Biochemistry 1998, 37, 217-226.
100. Lanzo, C. A.; Sutin, J.; Rowlinson, S.; Talley, J.; Marnett, L. J. Fluorescence quenching analysis of the association and dissociation of a diarylheterocycle to cyclooxygenase-1 and cyclooxygenase-2: dynamic basis of cyclooxygenase-2 selectivity. Biochemistry 2000, 39, 6228-6234.
101. Walker, M. C.; Kurumbail, R. G.; Kiefer, J. R.; Moreland, K. T.; Koboldt, C. M.; Isakson, P. C.; Seibert, K.; Gierse, J. K. A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors. Biochem. J. 2001, 357, 709-718.
102. Grosser, T.; Fries, S.; FitzGerald, G. A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest. 2006, 116, 4-15.
103. Ott, E.; Nussmeier, N. A.; Duke, P. C.; Feneck, R. O.; Alston, R. P.; Snabes, M. C.; Hubbard, R. C.; Hsu, P. H.; Saidman, L. J.; Mangano, D. T. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg. 2003, 125, 1481-1492.
104. McAdam, B. F.; Catella-Lawson, F.; Mardini, I. A.; Kapoor, S.; Lawson, J. A.; FitzGerald, G. A. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 272-277.
105. Moncada, S.; Higgs, E. A.; Vane, J. R. Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet 1977, 1, 18-20.
106. Topper, J. N.; Cai, J.; Falb, D.; Gimbrone, M. A., Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively upregulated by steady laminar shear stress. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 10417-10422.
107. Fries, S.; Grosser, T.; Price, T. S.; Lawson, J. A.; Kapoor, S.; DeMarco, S.; Pletcher, M. T.; Wiltshire, T.; FitzGerald, G. A. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology 2006, 130, 55-64.
108. Anning, P. B.; Coles, B.; Morton, J.; Wang, H.; Uddin, J.; Morrow, J. D.; Dey, S. K.; Marnett, L. J.; O'Donnell, V. B. Nitric oxide deficiency promotes vascular side-effects of cyclooxygenase inhibitors in vivo. Blood 2006, 108, 4059-4062.
109. Hippisley-Cox, J.; Coupland, C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. Br. Med. J. 2005, 330, 1366.
110. Garcia Rodriguez, L. A.; Gonzalez-Perez, A. Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. BMC Med. 2005, 3, 17.
111. Kearney, P. M.; Baigent, C.; Godwin, J.; Halls, H.; Emberson, J. R.; Patrono, C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Br. Med. J. 2006, 332, 1302-1308.
112. FitzGerald, G. A.; Patrono, C. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 2001, 345, 433-442.
113. Arber, N.; Eagle, C. J.; Spicak, J.; Racz, I.; Dite, P.; Hajer, J.; Zavoral, M.; Lechuga, M. J.; Gerletti, P.; Tang, J.; Rosenstein, R. B.; Macdonald, K.; Bhadra, P.; Fowler, R.; Wittes, J.; Zauber, A. G.; Solomon, S. D.; Levin, B. Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 2006, 355, 885-895.
114. Thun, M. J.; Henley, S. J.; Patrono, C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl. Cancer Inst. 2002, 94, 252-266.
115. Bertagnolli, M. M.; Eagle, C. J.; Zauber, A. G.; Redston, M.; Solomon, S. D.; Kim, K.; Tang, J.; Rosenstein, R. B.; Wittes, J.; Corle, D.; Hess, T. M.; Woloj, G. M.; Boisserie, F.; Anderson, W. F.; Viner, J. L.; Bagheri, D.; Burn, J.; Chung, D. C.; Dewar, T.; Foley, T. R.; Hoffman, N.; Macrae, F.; Pruitt, R. E.; Saltzman, J. R.; Salzberg, B.; Sylwestrowicz, T.; Gordon, G. B.; Hawk, E. T. Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med. 2006, 355, 873-884.
116. Psaty, B. M.; Potter, J. D. Risks and benefits of celecoxib to prevent recurrent adenomas. N. Engl. J. Med. 2006, 355, 950-952.
117. Steinbach, G.; Lynch, P. M.; Phillips, R. K.; Wallace, M. H.; Hawk, E.; Gordon, G. B.; Wakabayashi, N.; Saunders, B.; Shen, Y.; Fujimura, T.; Su, L. K.; Levin, B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 2000, 342, 1946-1952.